Timmune

Timmune is a clinical-stage biotechnology company dedicated to the development of next-generation T-cell receptor (TCR) therapies for solid tumors. The company leverages its proprietary TCR discovery platform to identify high-affinity, tumor-specific TCRs that target intracellular antigens presented by HLA molecules. Its lead candidate, T-101, is an autologous TCR-T therapy targeting HBV-related hepatocellular carcinoma, currently undergoing Phase 1 clinical evaluation. Timmune's pipeline also includes programs targeting NY-ESO-1 and MAGE-A4 for various solid malignancies. With operations in both the United States and China, the company is positioned to address global unmet needs in oncology through precision immunotherapy.